AIM/IMM (AIM/IMM)

London Stock Exchange AIM: AIM/IMM · GBX

GBX 3.68

-0.33 (-8.1%)· Recorded snapshot

Market cap	23M
Net income (ttm)	-4.7M
EPS (ttm)	-GBX 0.01
Shares out	625.3M
Volume	1,290,583
Beta	3.02

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -4.7M
EPS (ttm): -GBX 0.01
Market cap: 23M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-432.8

P25 n/aP50 n/aP75 n/a

ROIC-137.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AIM/IMM indicators

Market & fundamental data

Available fields

168

Groups with data

Currency

GBP

Showing 168 of 168 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	GBP
Country	United Kingdom
Country code	UK
Earnings date	2026-11-09
Employees	7
Employees change	1
Employees growth	16.67%
Enterprise value	GBX 22.3M
Exchange	London Stock Exchange AIM
Financial currency	GBP
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	1999
Industry	Biotechnology
Is primary listing	Yes
ISIN number	GB0033711010
Last earnings date	2025-11-07
Last refreshed	2026-10-28
Market cap	GBX 23M
Next earnings date	2026-11-09
Price	GBX 3.68
Price currency	GBX
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	aim/IMM
Website	https://www.immupharma.co.uk

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-24.06%
FCF / EV yield	-7.61%
FCF yield	-7.4%
P/B ratio	13.72x
Price / tangible book value	13.72x
Sector forward P/E	14.49x
Sector P/E	22.58x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	GBX -667,500
ROA	-63.37%
ROA (5Y)	-64.19%
ROCE	-130.18%
ROE	-432.82%
ROE (5Y)	-773.45%
ROIC	-137.35%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	7
Net income growth years	4
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	GBX -2,419
Depreciation and amortization	GBX -50,845
EBIT	GBX -2.4M
EBITDA	GBX -2.4M
EPS	GBX -0.01
FCF per share	GBX -0.00
Financing cash flow	GBX 2M
Free cash flow	GBX -1.8M
Free cash flow minus SBC	GBX -1.7M
Income taxes	GBX -254,096
Investing cash flow	GBX 7,415
Net cash flow	GBX 299,187
Net income	GBX -4.7M
Operating cash flow minus SBC	GBX -1.7M
Operating income	GBX -2.4M
Stock-based compensation	GBX -138,813

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	GBX 0.00
Debt / equity	0
Interest coverage	-0.81
Long-term assets	GBX 1.4M
Long-term liabilities	GBX 0
Net cash (debt)	GBX 695,836
Net cash / market cap	2.78%
Net cash growth	75.43%
Net debt / equity	-0.38
Piotroski F-Score	2
Property, plant and equipment	GBX 64,797
Shareholders' equity	GBX 1.8M
Tangible book value	GBX 1.8M
Tangible book value per share	GBX 0.00
Total assets	GBX 3.1M
Total cash	GBX 695,836
Total debt	GBX 0
Total liabilities	GBX 1.3M
WACC	20.85%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	GBX 1.7M
Current liabilities	GBX 1.3M
Current ratio	1.34
Net working capital	GBX -258,825
Quick ratio	0.78
Working capital	GBX 437,011

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-18.35%
Shareholder yield	-18.35%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-89.81%
10Y return CAGR	-20.42%
10Y total return	-89.81%
150-day SMA	GBX 4.06
15Y price change	-94.5%
15Y return CAGR	-17.58%
15Y total return	-94.5%
1D price change	-8.13%
1M price change	17.68%
1M total return	17.68%
1W price change	-6.15%
1W total return	-6.15%
1Y price change	-65.64%
1Y return CAGR	-65.67%
1Y total return	-65.64%
20-day SMA	GBX 3.71
200-day SMA	GBX 4.75
20Y price change	-94.36%
20Y return CAGR	-13.39%
20Y total return	-94.36%
3M price change	-10.51%
3M total return	-10.51%
3Y price change	124.77%
3Y return CAGR	30.98%
3Y total return	124.77%
50-day SMA	GBX 3.64
50-day SMA vs 200-day SMA	50under200
52-week high	GBX 12.00
52-week high date	2025-10-28
52-week low	GBX 3.10
52-week low date	2026-09-15
5Y price change	-44.71%
5Y return CAGR	-11.18%
5Y total return	-44.71%
6M price change	-15.93%
6M total return	-15.93%
All-time high	GBX 193.74
All-time high date	2018-01-03
All-time low	GBX 0.82
All-time low date	2024-03-01
Average true range (ATR)	GBX 0.64
Average volume	2.9M
Beta (1Y)	0.56
Beta (2Y)	0.94
Beta (5Y)	3.02
Change from 52-week high	-69.38%
Change from 52-week low	18.55%
Change from all-time high	-98.01%
Change from all-time low	368.13%
Change from open	-1.61%
Day's gap	-6.63%
Dollar volume	GBX 4.7M
High price	GBX 4.48
Low price	GBX 3.53
Monthly RSI	48.1
Open price	GBX 3.74
Position in 52-week range	15.71%
Previous close	GBX 4.00
Price vs 150-day SMA	-5.25%
Price vs 20-day SMA	3.75%
Price vs 200-day SMA	-18.97%
Price vs 50-day SMA	5.86%
Relative volume	0.45
RSI	52.52
Sharpe ratio	-0.44
Sharpe ratio (3Y)	0.75
Sharpe ratio (5Y)	0.46
Sortino ratio	-0.56
Sortino ratio (3Y)	1.93
Sortino ratio (5Y)	1.05
Volume	1.3M
Weekly RSI	45.87
YTD price change	-37.94%
YTD total return	-37.94%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	606.2M
Shares change (QoQ)	11.57%
Shares change (YoY)	18.35%
Shares held by insiders	0.6%
Shares held by institutions	70.24%
Shares outstanding	625.3M

Deeper analysis on AIM/IMM

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AIM/IMM report

Is a complete AIM/IMM research report available?

No complete published report is available for aim/IMM (AIM/IMM) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

AIM/IMM (AIM/IMM)

Price

Financial snapshot

Fair-value bridge

Latest news · AIM/IMM

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AIM/IMM indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AIM/IMM

Frequently asked questions